National Academy of Sciences Issues Landmark Statement on the Therapeutic Value of Medical Cannabis

Source: Daily Sheeple/National Academy of Sciences
Published: Jan 16, 2017
Author: Alex Pietrowski
Post Date: 2017-01-17 10:13:55 by Deckard
Views: 1985

In 2016, the Drug Enforcement Administration of the United States issued a long-awaited decision on the medical benefits of cannabis, and instead of validating what millions of people already know to be true about this healing plant, the DEA chose to keep intact the 1970 designation of cannabis as a schedule I substance, a drug which has, as they claim, no medical benefit.

Furthermore, in an even more egregious affront to justice and common sense, in December of 2016, the DEA made an overnight decision to create a new classification of schedule I drugs for cannabis extracts in order to stop the sale and consumption of CBD oil, a non-psychoactive derivative of cannabis which is known to have many health benefits.

These decisions contradict hundreds of studies, an abundance of medically verified success stories, and countless pieces of anecdotal evidence that cannabis in fact has wide-ranging medical value.

Seen as preposterous to those who support legalization, these rulings appear to be rooted in the status quo tyranny of the drug war and prison industrial complex, two monolithic cash cows which bring immense profit to those who persecute others for recreational and medical use of a plant. Now, however, this DEA’s attitude towards cannabis should come under even more scrutiny and criticism, as the National Academy of Sciences (NAS) has just released a press release which supports the claims that cannabis has therapeutic benefits.

“… the lack of any aggregated knowledge of cannabis-related health effects has led to uncertainty about what, if any, are the harms or benefits from its use.  We conducted an in-depth and broad review of the most recent research to establish firmly what the science says and to highlight areas that still need further examination.  As laws and policies continue to change, research must also.”

In the groundbreaking report released this week entitled The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017), the NAS issued a comprehensive, researched-backed statement on the validity of medical marijuana, including pros and cons, outlining its clinical effectiveness.

“The report states that there is conclusive evidence that marijuana can be used as a medicine. The report did not find clinical evidence for all conditions marijuana treatment is often associated with, but it recognizes its efficacy for treating many medical conditions such as “chronic pain in adults…chemotherapy-induced nausea and vomiting and multiple sclerosis spasticity symptoms.”” [Source]

Speaking on the significance of a statement such as this coming from such an authoriative scientific body as the NAS, Deputy Director of National Affairs at the Drug Policy Alliance, Michael Collins said:

“This report is vindication for all the many researchers, patients and healthcare providers who have long understood the benefits of medical marijuana. To have such a thorough review of the evidence conclude that there are benefits to medical marijuana should boost the case for federal reform. It also underlines how out of touch the DEA and other marijuana reform opponents are when they claim otherwise.” [Source]

Key findings in the NAS report of particular interest to advocates of legalization include the following:

  • Cannabis has significant therapeutic benefit in the treatment of chronic pain, for spasms caused by multiple-sclerosis, and in the reduction of discomfort for chemotherapy and radiation treatment patients.
  • Smoking cannabis does not increase the risk for cancers often associated with tobacco use.

The NAS report does not appear to show favoritism in its findings, duly noting and reporting evidence of both the positive and negative aspects of chronic cannabis usage, which includes the increased risk of mental health issues and psychosocial issues due to overuse. However, the report should be considered a win for those advocating for the legalization of cannabis-based therapeutic medicines and remedies, as well as a rejection of the DEA’s classification of cannabis and cannabis extracts as substances devoid of medical benefit.

Related Reads

UK Just Reclassified CBD Oil as Medicine, Right as US DEA Puts It in Same Class with Heroin

In Under 4 Minutes, Video Exposes Vile Nature of DEA Classifying CBD Oil as Schedule 1

DEA Blames the Media for Making It Harder to Arrest People over Weed

Cannabis Is Now Legal in These States

Why EVERYONE Should Care About the Goverment’s War on Cannabis and Kratom

Post Comment   Private Reply

#1: U don't know me    To: Deckard (#0)

You're going to get all the big pharma supporters and stock holders upset again.

U don't know me posted on 2017-01-17 14:45:10   Reply   Private Reply

#2: nolu chan    To: Deckard (#0)

In the groundbreaking report released this week entitled The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017), the NAS issued a comprehensive, researched-backed statement on the validity of medical marijuana, including pros and cons, outlining its clinical effectiveness.

“The report states that there is conclusive evidence that marijuana can be used as a medicine. The report did not find clinical evidence for all conditions marijuana treatment is often associated with, but it recognizes its efficacy for treating many medical conditions such as “chronic pain in adults…chemotherapy-induced nausea and vomiting and multiple sclerosis spasticity symptoms.”” [Source]

Above link provided as source:

http://www.drugpolicy.org/news/2017/01/national-academy-sciences-finds-conclusive-evidence-marijuana-effective-medicine?utm_campaign=fy17social&utm_medium=social&utm_source=1701fbc3NASreportpr

The actual conclusions to the actual report are readily available.

NAS Report Conclusions

NAS link: http://nationalacademies.org/hmd/~/media/Files/Report%20Files/2017/Cannabis-Health-Effects/cannabis-conclusions.pdf?_ga=1.252664265.1336370589.1484694224

CONCLUSIONS FOR: THERAPEUTIC EFFECTS

There is conclusive or substantial evidence that cannabis or cannabinoids are effective:

  • For the treatment for chronic pain in adults (cannabis) (4-1)

  • Antiemetics in the treatment of chemotherapy-induced nausea and vomiting (oral cannabinoids) (4-3)

  • For improving patient-reported multiple sclerosis spasticity symptoms (oral cannabinoids) (4-7a)

There is moderate evidence that cannabis or cannabinoids are effective for:

  • Improving short-term sleep outcomes in individuals with sleep disturbance associated with obstructive sleep apnea syndrome, fibromyalgia, chronic pain, and multiple sclerosis (cannabinoids, primarily nabiximols) (4-19)

There is limited evidence that cannabis or cannabinoids are effective for:

  • Increasing appetite and decreasing weight loss associated with HIV/AIDS (cannabis and oral cannabinoids) (4-4a)

  • Improving clinician-measured multiple sclerosis spasticity symptoms (oral cannabinoids) (4-7a)

  • Improving symptoms of Tourette syndrome (THC capsules) (4-8)

  • Improving anxiety symptoms, as assessed by a public speaking test, in individuals with social anxiety disorders (cannabidiol) (4-17)

  • Improving symptoms of posttraumatic stress disorder (nabilone; one single, small fair-quality trial) (4-20)

There is limited evidence of a statistical association between cannabinoids and:

  • Better outcomes (i.e., mortality, disability) after a traumatic brain injury or intracranial hemorrhage (4-15)

There is limited evidence that cannabis or cannabinoids are ineffective for:

  • Improving symptoms associated with dementia (cannabinoids) (4-13)

  • Improving intraocular pressure associated with glaucoma (cannabinoids) (4-14)

  • Reducing depressive symptoms in individuals with chronic pain or multiple sclerosis (nabiximols, dronabinol, and nabilone) (4-18)

nolu chan posted on 2017-01-17 18:35:38   Reply   Private Reply

#3: nolu chan    To: All (#2)

Also:

There is no or insufficient evidence to support or refute the conclusion that cannabis or cannabinoids are an effective treatment for:

  • Cancers, including glioma (cannabinoids) (4-2)

  • Cancer-associated anorexia cachexia syndrome and anorexia nervosa (cannabinoids) (4-4b)

  • Symptoms of irritable bowel syndrome (dronabinol) (4-5)

  • Epilepsy (cannabinoids) (4-6)

  • Spasticity in patients with paralysis due to spinal cord injury (cannabinoids) (4-7b)

  • Symptoms associated with amyotrophic lateral sclerosis (cannabinoids) (4-9)

  • Chorea and certain neuropsychiatric symptoms associated with Huntington’s disease (oral cannabinoids) (4-10)

  • Motor system symptoms associated with Parkinson’s disease or the levodopa-induced dyskinesia (cannabinoids) (4-11)

  • Dystonia (nabilone and dronabinol) (4-12)

  • Achieving abstinence in the use of addictive substances (cannabinoids) (4-16)

  • Mental health outcomes in individuals with schizophrenia or schizophreniform psychosis (cannabidiol) (4-21)

nolu chan posted on 2017-01-17 19:19:18   Reply   Private Reply

#4: A Pole    To: nolu chan (#3)

Why do you care?

A Pole posted on 2017-01-17 19:24:12   Reply   Private Reply

#5: tpaine    To: A Pole, y'all (#4)

To: nolu chan

Why do you care?

He's probably a big pharma supporter and/or stock holder, ----- plus, of course, we're all aware of his know-it-all (at length) and bleeding heart manias.

tpaine posted on 2017-01-17 19:39:34   Reply   Private Reply

#6: nolu chan    To: A Pole (#4)

Why do you care?

I'm allergic to bullshit. What is your objection to the words of the actual report as opposed to some doper?

nolu chan posted on 2017-01-18 01:38:53   Reply   Private Reply